Literature DB >> 20499227

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Margareta Ramsjö1, Eleni Aklillu, Lilleba Bohman, Magnus Ingelman-Sundberg, Hyung-Keun Roh, Leif Bertilsson.   

Abstract

OBJECTIVES: To compare CYP2C19 enzyme activity between Swedes and Koreans controlling for the effect of CYP2C19 genotype, sex, oral contraceptive use, and smoking habits.
METHODS: CYP2C19 activity was determined in 185 healthy Swedish and 150 Korean subjects as the omeprazole/5-hydroxyomeprazole ratio (metabolic ratio; MR) using high-performance liquid chromatography. Genotyping was performed by PCR using Taqman assay.
RESULTS: As expected, a higher incidence of poor metabolizers (PM) was found in Koreans (14%) compared with Swedes (3.8%) and the frequency of the CYP2C19 17 allele was very low in Koreans (0.3%). Among subjects homozygous for CYP2C19 1, Koreans displayed significantly lower CYP2C19 enzyme activity than Swedes (p < 0.000001). Interestingly, in Koreans a pronounced gender difference was apparent: females (n = 24) had significantly lower MR than males (n = 30; p < 0.0001), but such a gender difference was not seen among Swedes. Swedish OC users had a higher MR than non-users (p < 0.00001), whereas OC was only used by one Korean. No effects of smoking were observed.
CONCLUSIONS: We find specific gender-dependent effects of CYP2C19 activity in Koreans, but not in Swedes. Controlling for the effect of genotype and sex, Koreans display lower CYP2C19 activity than Swedes. The genetic, epigenetic or environmental basis for this difference remains to be identified.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20499227     DOI: 10.1007/s00228-010-0835-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

2.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

3.  Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.

Authors:  H G Xie; S L Huang; Z H Xu; Z S Xiao; N He; H H Zhou
Journal:  Pharmacogenetics       Date:  1997-04

4.  No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.

Authors:  K Laine; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

5.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Weiling; B Wilffert; L F de Leij; R A de Zeeuw; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1999-05       Impact factor: 2.953

Review 7.  Some aspects of genetic polymorphism in the biotransformation of antidepressants.

Authors:  Kim Brøsen
Journal:  Therapie       Date:  2004 Jan-Feb       Impact factor: 2.070

8.  The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.

Authors:  Magnus Christensen; Katarina Andersson; Per Dalén; Rajaa A Mirghani; Gary J Muirhead; Anna Nordmark; Gunnel Tybring; Anneli Wahlberg; Umit Yaşar; Leif Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

9.  A highly annotated whole-genome sequence of a Korean individual.

Authors:  Jong-Il Kim; Young Seok Ju; Hansoo Park; Sheehyun Kim; Seonwook Lee; Jae-Hyuk Yi; Joann Mudge; Neil A Miller; Dongwan Hong; Callum J Bell; Hye-Sun Kim; In-Soon Chung; Woo-Chung Lee; Ji-Sun Lee; Seung-Hyun Seo; Ji-Young Yun; Hyun Nyun Woo; Heewook Lee; Dongwhan Suh; Seungbok Lee; Hyun-Jin Kim; Maryam Yavartanoo; Minhye Kwak; Ying Zheng; Mi Kyeong Lee; Hyunjun Park; Jeong Yeon Kim; Omer Gokcumen; Ryan E Mills; Alexander Wait Zaranek; Joseph Thakuria; Xiaodi Wu; Ryan W Kim; Jim J Huntley; Shujun Luo; Gary P Schroth; Thomas D Wu; HyeRan Kim; Kap-Seok Yang; Woong-Yang Park; Hyungtae Kim; George M Church; Charles Lee; Stephen F Kingsmore; Jeong-Sun Seo
Journal:  Nature       Date:  2009-07-08       Impact factor: 49.962

10.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

View more
  19 in total

1.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

2.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

Review 3.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

4.  Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Authors:  Eileen B Lawson; Jerry C Wu; R Michael Baldwin; Magnus Ingelman-Sundberg; Staffan Rosenborg; Dong-Seok Yim; Ophelia Q P Yin; Edmund V Capparelli; Joseph D Ma
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

5.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

6.  Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Authors:  Fazleen H M Hatta; Lay Kek Teh; Anders Helldén; Karin Engström Hellgren; Hyung-Keun Roh; Mohd Zaki Salleh; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

7.  CYP2C19 genetics in fatal carisoprodol intoxications.

Authors:  Gudrun Høiseth; Umair Majid; Jørg Mørland; Jørgen G Bramness; Espen Molden
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

8.  CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.

Authors:  Paulo C J L Santos; Renata A G Soares; Diogo B G Santos; Raimundo M Nascimento; George L L M Coelho; José C Nicolau; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  BMC Med Genet       Date:  2011-01-19       Impact factor: 2.103

9.  Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.

Authors:  Rasmus S Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria S Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2010-07-28       Impact factor: 2.953

10.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.

Authors:  Su-Jun Lee
Journal:  Front Genet       Date:  2013-02-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.